{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"4"}]}],"title":"Partial Remission"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"6"}]}],"title":"Very Good Partial Remission"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}],"title":"Complete Remission"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}]}],"title":"Stringent Complete Remission"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}],"title":"Progressive Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"16"}],"units":"Participants"}],"description":"Best response was assessed by the International Myeloma Working Group response criteria. Partial Remission (PR) is 50% or greater reduction of serum M-protein and 90% or greater reduction in 24-h urinary M-protein. Progressive Disease (PD) is increases of greater or equal to 25% from the lowest post-treatment (nadir) value in serum M-component or urine component or percentage of bone marrow plasma cells. Definite development of new bone lesions or new plasmacytoma. Very Good Partial Remission (VGPR) is serum and urine M-protein detectable by immunofixation but not on electrophoresis. Stringent Complete Remission (sCR) is normal free light chain ratio and absence of clonal cells in bone marrow by immunohistochemistry. Complete Remission is negative immunofixation on the serum and urine. Stable Disease (SD) is not meeting criteria for CR, VGPR, PR or PD.","groups":[{"description":"Dose Escalation with 5 dose levels based on the patients actual bodyweight\n\nCyclophosphamide: 300 mg/m\\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3\n\nFludarabine: 30 mg/m\\^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3\n\nAnti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells: 0.3x10\\^6- 15.0x10\\^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0","id":"OG000","title":"0.3 x 10^6 CAR-BCMA T-cells Infused"},{"description":"Dose Escalation with 5 dose levels based on the patients actual bodyweight\n\nCyclophosphamide: 300 mg/m\\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3\n\nFludarabine: 30 mg/m\\^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3\n\nAnti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells: 0.3x10\\^6- 15.0x10\\^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0","id":"OG001","title":"1 x 10^6 CAR-BCMA T-cells Infused"},{"description":"Dose Escalation with 5 dose levels based on the patients actual bodyweight\n\nCyclophosphamide: 300 mg/m\\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3\n\nFludarabine: 30 mg/m\\^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3\n\nAnti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells: 0.3x10\\^6- 15.0x10\\^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0","id":"OG002","title":"3 x 10^6 CAR-BCMA T-cells Infused"},{"description":"Dose Escalation with 5 dose levels based on the patients actual bodyweight\n\nCyclophosphamide: 300 mg/m\\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3\n\nFludarabine: 30 mg/m\\^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3\n\nAnti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells: 0.3x10\\^6- 15.0x10\\^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0","id":"OG003","title":"9 x 10^6 CAR-BCMA T-cells Infused"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"One participant in Group 9x10(6) did not get CAR T-cells and was deemed ineligible, and 3 participants in Group 9x10(6) were found to be ineligible for treatment.","reportingStatus":"POSTED","timeFrame":"From start of treatment up to 84 weeks","title":"Number of Participants With Best Response","type":"SECONDARY","unitOfMeasure":"Participants"}